Categories: NewsSports medicine

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2022 Financial Results on March 1, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

WARSAW, Ind., Feb. 14, 2023 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, after the market closes. OrthoPediatrics will host a conference call on Wednesday, March 1, 2023, at 8:00 a.m. ET to discuss the results.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be available for replay for at least 90 days after the event.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 46 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com.

Investor Contact:
Philip Taylor
Gilmartin Group
philip@gilmartinir.com
415-937-5406

Staff

Recent Posts

IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment

DiaSafe™, IR-MED's second product, is being developed to provide safe, real-time optical readings of biomarkers…

5 minutes ago

NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025

Financial results to be released before market open; Conference call to be conducted at 9:00…

5 minutes ago

Cannabix Technologies Receives NHTSA Approval for BreathLogix Workplace Series Alcohol Breathalyzer

Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of…

5 minutes ago

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Company continues to expand global IP coverage and claims to major markets, now extending to…

6 minutes ago

SS Innovations Reiterates Guidance for First Quarter 2025 and Provides Commentary on Second Quarter 2025 Order Trends

FORT LAUDERDALE, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company”…

6 minutes ago

BioSig Enters into an LOI to Merge with Streamex Exchange Corp. Creating a Publicly Listed Real-World Asset Tokenization Company Led by Seasoned Industry Executives

Los Angeles, CA, May 05, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig”…

6 minutes ago